Zwitserland - Duits - Swissmedic (Swiss Agency for Therapeutic Products)

viiv healthcare gmbh - cabotegravirum - depot-injektionssuspension - cabotegravirum 400 mg, mannitolum, polysorbatum 20, macrogolum 3350, aqua ad iniectabile, ad solutionem pro 2 ml. - hiv-infektion - synthetika

Zwitserland - Duits - Swissmedic (Swiss Agency for Therapeutic Products)

viiv healthcare gmbh - cabotegravirum - depot-injektionssuspension - cabotegravirum 600 mg, mannitolum, polysorbatum 20, macrogolum 3350, aqua ad iniectabile, ad solutionem pro 3 ml. - hiv-infektion - synthetika

Europese Unie - Duits - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegravir - hiv-infektionen - antivirale mittel zur systemischen anwendung - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 und 5.